# CellCentric funding rounds and investors

As of 19 Nov 2026, CellCentric has raised $340M across 2 verified rounds on record, plus 5 rounds still being checked; latest: $220 million Series D led by Venrock Healthcare Capital Partners, announced 6 May 2026.

A drug-discovery platform

Website: https://cellcentric.com  
Headquarters: Cambridge, England  
Page: https://fireround.dev/companies/cellcentric

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-05-06 | Series D | $220 million | Venrock Healthcare Capital Partners | Fidelity Management & Research Company, Sofinnova Partners, HBM Healthcare Investments, RA Capital Management, Forbion, Pfizer Ventures, Avego BioScience Capital, American Cancer Society BrightEdge | [cellcentric.com](https://www.cellcentric.com/press-release/cellcentric-announces-oversubscribed-220-million-series-d-financing-to-advance-pivotal-trials-of-inobrodib-in-multiple-myeloma), [axios.com](https://www.axios.com/pro/biotech-deals/2026/05/06/cellcentric-raises-220m-myeloma-drug), [fiercebiotech.com](https://www.fiercebiotech.com/biotech/cellcentric-announces-220m-series-d-advance-drug-through-registration-and-potential-ipo) |
| 2025-05-19 | Series C | $120 million | RA Capital Management, Forbion | Avego BioScience Capital, BrightEdge | [cellcentric.com](https://www.cellcentric.com/press-release/cellcentric-secures-120-million-investment-to-advance-inobrodib-for-treating-multiple-myeloma), [fiercebiotech.com](https://www.fiercebiotech.com/biotech/pfizer-backed-cellcentric-secures-120m-further-myeloma-trials) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.
